76 completed, 46 unknown, 31 recruiting, 17 not yet recruiting. 67 Not applicable, 33 Phase 2, 16 Phase 1, 13 Phase 3, 1 Early Phase 1.
Follow Institut Paoli-Calmettes: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluation of Naloxegol in the Prevention of POI After Cystectomy Naloxégol oxalate, Placebo oral tablet - Bladder Cancer, Cystostomy; Complications | Phase 2 | Withdrawn | Institut Paoli-Calmettes | 2032-01-01 | 2026-10-14 | |
| Predicting Pancreatic Fistula After Pancreatic Surgery Using Preoperative Immunity blood sampling - Pancreatic Cancer | Not yet recruiting | Institut Paoli-Calmettes | 310 | 2027-01-04 | 2026-09-18 | |
| Reduction of Neoadjuvant Treatment in Early Triple-Negative Breast Cancer Pembrolizumab - Early Triple-Negative Breast Cancer | Phase 2 | Not yet recruiting | Institut Paoli-Calmettes | 84 | 2026-11-01 | 2026-10-05 |
| FLUDARABINE-TREOSULFAN REDUCED INTENSITY CONDITIONING REGIMEN PRIOR HAPLOIDENTICAL STEM CELL TRANSPLANTATION WITH POST TRANSPLANTATION CYCLOPHOSPHAMIDE FOR OLDER AND/OR FRAIL PATIENTS WITH AML fludarabine and treosulfan - Acute Myeloid Leukemia | Phase 2 | Not yet recruiting | Institut Paoli-Calmettes | 77 | 2026-10-10 | 2026-05-20 |
| Surgery Versus Stereotactic Ablative Radiotherapy for Patients With Locally Advanced Pancreatic Cancer With Favourable Biological Response Following Induction Chemotherapy Pancreatic surgery, MRI guided stereotactic ablative radiotherapy - Locally Advanced Pancreatic Carcinoma (LAPC) | Phase 3 | Not yet recruiting | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA) | 230 | 2026-10-01 | 2026-10-09 |
| Feasibility Study of a Sports-Inspired Onco-Coaching Progranm for Young Adults i Cancer Remission Solid and Hematologic Cancer | Recruiting | Institut Paoli-Calmettes | 19 | 2026-08-03 | 2026-10-06 | |
| Reduction of Hematologic Toxicity in Locally Advanced Cervical Cancers radiotherapy with bone marrow contouring - Cervical Cancer by FIGO Stage 2018 | Not applicable | Not yet recruiting | Institut Paoli-Calmettes | 72 | 2026-07-15 | 2026-03-10 |
| Post-immunotherapy Nephrectomy for Metastatic Kidney Cancer After Complete or Major Response to Systemic Therapy nephrectomy - Kidney Cancer | Not applicable | Recruiting | Institut Paoli-Calmettes | 60 | 2026-05-13 | 2026-10-14 |
| A Trial Using Transcriptomic Signatures to Personalize Neoadjuvant Chemotherapy (NAC) for Patients With Resectable Borderline Pancreatic Adenocarcinoma (PDAC) mFOLFIRINOX (modified FOLFIRINOX) - Pancreas Adenocarcinoma (MSI-H), Pancreatic Cancer Resectable | Not applicable | Not yet recruiting | Institut Paoli-Calmettes | 367 | 2026-05-01 | 2026-05-18 |
| IMMUNO-LUNG : Identification of Biomarkers and Therapeutic Targets for Pulmonary Immunotherapy prospective collection of blood and tumor samples - Non-small Cell Lung Cancer | Not applicable | Recruiting | Institut Paoli-Calmettes | 200 | 2026-02-12 | 2026-05-27 |
| De-Escalation Study Evaluating Venetoclax and Azacitidine Discontinuation in AML Responding Patients Venetoclax, Azacitidine - Acute Myeloid Leukemia | Phase 2 | Recruiting | Institut Paoli-Calmettes | 50 | 2026-02-04 | 2026-03-13 |
| Metabolic Reprogramming and Microenvironment in Pancreatic Adenocarcinoma Biopsy collection, Blood collection - Pancreatic Adenocarcinoma Metastatic | Recruiting | Institut Paoli-Calmettes | 64 | 2025-09-11 | 2026-06-24 | |
| Bevacizumab-based Chemotherapy Adapted to Bevacizumab Pharmacokinetics in 1st-line Treatment Avastin, 25 Mg/mL Intravenous Solution - Unresectable Metastatic Colorectal Cancer | Phase 3 | Recruiting | University Hospital, Tours | 244 | 2025-03-04 | 2026-06-16 |
| Study of Radiology Manipulator Work Validation by the Radiologist Solid Cancer | Recruiting | Institut Paoli-Calmettes | 87 | 2024-12-12 | 2025-03-25 | |
| Efficacy of First-Line Gemcitabine Chemotherapy in GemCore+ Metastatic Pancreatic Adenocarcinoma Patients Analyze of GemCore status - Cancer Of Pancreas | Not applicable | Recruiting | Institut Paoli-Calmettes | 100 | 2024-05-23 | 2026-09-29 |
| Evaluation of DASATINIB Monotherapy Efficacy in Acute Myeloid Leukemia Patients Refractory to VENETOCLAX-AZACITIDINE Dasatinib - Acute Myeloid Leukemia | Phase 2 | Suspended | Institut Paoli-Calmettes | 35 | 2024-05-22 | 2026-10-01 |
| I/II Phase Study Evaluating M1774 in Combination With Fulvestrant in HR+ and HER2- Advanced Breast Cancers M1774, Fulvestrant injection - Breast Cancer | Phase 1 / Phase 2 | Not yet recruiting | Institut Paoli-Calmettes | 57 | 2024-05-01 | 2024-03-29 |
| PROPHYLAXIS OF GVH IN ELDERLY PATIENTS RECEIVING HAPLOIDENTICAL ALLOGENIC HEMATOPOIETIC STEM CELL TRASNPLANTATION USE OF A LOW DOSE ANTI-LYMPHOCYTIC SERUM Thymoglobulin Injectable Product - Hematological Malignancy | Phase 2 | Unknown | Institut Paoli-Calmettes | 27 | 2024-03-31 | 2024-02-20 |
| AlloLife - Life After Transplantation Technology supported, coordinated survivorship care using wearable devices, supportive patient-apps and cardio-oncology physician apps - Survivorship, Stem Cell Transplant Complications | Not applicable | Unknown | University Hospital, Essen | 192 | 2024-03-01 | 2021-11-16 |
| Evaluation of VISIOCYT Bladder Cytology in Real Life Bladder Cancer | Completed | Institut Paoli-Calmettes | 701 | 2023-11-08 | 2026-03-19 |
Showing 20 of 193. Sign in to see all of them.
Breast Neoplasms (23) · Leukemia, Myeloid, Acute (19) · Pancreatic Neoplasms (19) · Hematologic Neoplasms (11) · Neoplasms (10) · Myelodysplastic Syndromes (9) · Prostatic Neoplasms (8) · Ovarian Neoplasms (7) · Leukemia (6) · Leukemia, Lymphocytic, Chronic, B-Cell (6) · Lymphoma, Non-Hodgkin (6) · Multiple Myeloma (6) · Congenital Abnormalities (5) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (5) · Endometrial Neoplasms (4)
Data Collection (14) · Blood Specimen Collection (13) · Busulfan (6) · Surveys and Questionnaires (4) · Antilymphocyte Serum (3) · Cyclophosphamide (3) · Paclitaxel (3) · Radiotherapy (3) · fludarabine phosphate (3) · Bevacizumab (2) · Cytarabine (2) · Drug Therapy (2) · Gemcitabine (2) · Interviews as Topic (2) · Lenalidomide (2)
France (160) · Italy (3) · Romania (3) · Spain (3) · United Kingdom (3) · Denmark (2) · Germany (2) · Monaco (2) · Norway (2) · United States (2) · Belgium (1) · Netherlands (1) · Switzerland (1)
Didier Blaise, MD (4) · Adrian Saftoiu, Professor (2) · Norbert Vey, MD (2) · Olivier Turrini, PD (2) · Raynier Devillier, MD,PhD (2)
PMID 12893206, PMID 15171047, PMID 15350354, PMID 15368961, PMID 16567771, PMID 16622123, PMID 16801631, PMID 16875720, PMID 17416765, PMID 17635951, PMID 18662417, PMID 19046847, PMID 19189349, PMID 19190154, PMID 19395008, PMID 19751997, PMID 20609464, PMID 20818904, PMID 21126687, PMID 21248744, PMID 21437851, PMID 21708517, PMID 21761160, PMID 21963957, PMID 22014859, PMID 22076253, PMID 22378286, PMID 22762150, PMID 22956590, PMID 23464850, PMID 23475556, PMID 24327581, PMID 24399079, PMID 24671869, PMID 24874284, PMID 24880617, PMID 24889689, PMID 25010056, PMID 25013076, PMID 25417756, PMID 25455630, PMID 25515656, PMID 25550141, PMID 25613119, PMID 25792386, PMID 25935731, PMID 26008969, PMID 26142442, PMID 26205609, PMID 26482833
2016 (2), 2018 (2), 2019 (2), 2025 (2)